- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01505803
The Effect of a Nutritional Supplement in Individuals With Type 2 Diabetes Mellitus: a Pilot Study
The Effect of a Nutritional Supplement on Cardiometabolic, Inflammatory, and Oxidative Stress Markers in Individuals With Type 2 Diabetes Mellitus: a Pilot Study
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The prevalence of type 2 DM and related-complications continues to increase. Diet is a significant factor in the aetiology of type 2 DM. Intakes of zinc and omega 3 fatty acids may modulate glycaemic control, lipid metabolism, and inflammatory processes in the disease. Zinc is involved in many biological processes that include enzyme action, stabilisation of cell membranes, regulation of gene expression, and cell signalling. Zinc supplementation has been demonstrated to improve glycaemic control in both animals and humans. The normalising effect of zinc on glucose homeostasis may relate to its involvement in insulin metabolism. Zinc functions in the synthesis, storage, secretion, and action of insulin. Omega-3 also enhances glycaemic control and dietary supplementation with omega-3 polyunsaturated fatty acids has been shown to improve insulin sensitivity in subjects with DM. Both zinc and omega-3 function to mediate lipid metabolism. Zinc supplementation has been found to be associated with a beneficial increase in HDL cholesterol concentrations in individuals with type 2 DM. The mechanism may again involve insulin, which has been proposed as an independent predictor of plasma HDL. Omega-3 directly activates transcription factors that regulate lipid metabolism and is known to decrease serum triglyceride levels in DM. Zinc appears to beneficially impact oxidative stress-related parameters in DM via a range of mechanisms, including the regulation of copper,zinc superoxide dismutase, metallothionein, NF-κB and nitric oxide signaling. The purpose of this pilot study is to explore the effect of zinc and omega 3 supplementation on hyperglycaemia, dyslipidaemia, chronic inflammation, and oxidative stress in a population with type 2 DM.
This study will recruit 48 postmenopausal women with type 2 DM. Participants will be randomly allocated to one of 4 groups for a period of 12 weeks: placebo, zinc, omega 3, or zinc + omega 3 supplementation. Usual dietary intake will be assessed before and after the trial period using 2-day estimated food records, which will be checked by a research dietitian. Blood samples will be collected from all participants at the start of the intervention (week 0) then at 4 weekly intervals (weeks 4, 8, 12) by qualified phlebotomists. Blood samples will be analysed for plasma zinc, plasma lipids and fatty acids, markers of inflammation and oxidative stress, and indicators of glycaemic control. An aliquot of blood will also be used for the measurement of zinc transporter mRNA levels utilising real-time quantitative PCR techniques.
Type d'étude
Inscription (Réel)
Phase
- La phase 1
Contacts et emplacements
Lieux d'étude
-
-
New South Wales
-
Sydney, New South Wales, Australie, 2006
- University of Sydney
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Female, postmenopausal
- Type 2 diabetes (controlled by diet and lifestyle; or oral hypoglycaemic medication (i.e. metformin) for not more than 7 years)
- Normal Glomerular Filtration Rate (GFR) and normal microalbumin/creatine ratio
- No nutritional supplements in the 6 weeks prior to the trial & continuing through the trial period
- Non-smoking
Exclusion Criteria:
- Diagnosed with current major illness (renal disease, significant cardiovascular disease, gastrointestinal disorders, cancer, or other significant disorder likely to interfere with zinc metabolism)
- Taking medications that are likely to interfere with zinc metabolism
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Comparateur placebo: Supplément placebo
|
Participants will receive placebo supplements each day for 12 weeks.
|
Comparateur actif: Zinc supplement
|
Participants will receive 40 mg of zinc each day for 12 weeks.
Participants will receive placebo supplements each day for 12 weeks.
|
Comparateur actif: Omega 3 supplement
|
Participants will receive placebo supplements each day for 12 weeks.
Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
|
Comparateur actif: Zinc and omega 3 supplements
|
Participants will receive 40 mg of zinc each day for 12 weeks.
Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Plasma lipids (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides)
Délai: 12 weeks
|
12 weeks
|
Glycaemic control (glucose, insulin, HbA1c)
Délai: 12 weeks
|
12 weeks
|
Inflammation & oxidative stress (CRP, TNF-α, IL-1, IL-2, IL-6, IL-10 F2 isoprostanes, NF-κB, MPO, other)
Délai: 12 weeks
|
12 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Zinc transporter mRNA expression in peripheral blood mononuclear cells
Délai: 12 weeks
|
12 weeks
|
Plasma zinc
Délai: 12 weeks
|
12 weeks
|
Plasma fatty acids
Délai: 12 weeks
|
12 weeks
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Samir Samman, University of Sydney
- Chercheur principal: Meika Foster, University of Sydney
Publications et liens utiles
Publications générales
- Foster M, Petocz P, Samman S. Effects of zinc on plasma lipoprotein cholesterol concentrations in humans: a meta-analysis of randomised controlled trials. Atherosclerosis. 2010 Jun;210(2):344-52. doi: 10.1016/j.atherosclerosis.2009.11.038. Epub 2009 Nov 29.
- Foster M, Samman S. Zinc and redox signaling: perturbations associated with cardiovascular disease and diabetes mellitus. Antioxid Redox Signal. 2010 Nov 15;13(10):1549-73. doi: 10.1089/ars.2010.3111.
- Foster M, Hancock D, Petocz P, Samman S. Zinc transporter genes are coordinately expressed in men and women independently of dietary or plasma zinc. J Nutr. 2011 Jun;141(6):1195-201. doi: 10.3945/jn.111.140053. Epub 2011 Apr 13.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- HREC 12392
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète sucré, Type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
Asahi Kasei Pharma CorporationRecrutement
-
University of MinnesotaActif, ne recrute pasHypoglycémie | Diabète sucré de type 2États-Unis
-
University of Campania "Luigi Vanvitelli"ComplétéDiabète sucré de type 2Italie
-
University of LiverpoolAstraZeneca; Clinical Practice Research DatalinkActif, ne recrute pas
-
Regor Pharmaceuticals Inc.RésiliéDiabète sucré de type 2États-Unis
-
Charles Drew University of Medicine and ScienceNational Center for Research Resources (NCRR)Résilié
-
Population Health Research InstituteNovo Nordisk A/SComplétéDiabète sucré de type 2Canada
-
Northwell HealthPatient-Centered Outcomes Research InstituteComplétéDiabète sucré de type 2 | Diabète de type 2États-Unis
Essais cliniques sur Zinc supplements
-
International Centre for Diarrhoeal Disease Research...Complété
-
University of California, DavisBill and Melinda Gates Foundation; Helen Keller International; Université Polytechnique...ComplétéMalnutritionBurkina Faso
-
Lesaffre InternationalComplété
-
Instituto Nacional de Salud Publica, MexicoUNICEFComplétéDiarrhée infantile | Diarrhée ; aiguëMexique
-
Tufts UniversityBoston University; Boston Medical Center; Hebrew SeniorLifeComplétéTrouble de la fonction immunitaire
-
CES UniversityNutreva S.A.S.; Foundation Child Care - FANComplétéDiarrhée | Infection respiratoire aiguëColombie
-
University of UtahIntermountain Research and Medical FoundationRésiliéLe zinc entéral pour améliorer la croissance des nourrissons à risque de dysplasie bronchopulmonaireDysplasie bronchopulmonaire | Échec de la croissance | Nourrisson, prématuréÉtats-Unis
-
National University Hospital, SingaporeNational University, SingaporeComplétéDiabète sucré, non dépendant de l'insuline
-
Hormozgan University of Medical SciencesComplété
-
UCSF Benioff Children's Hospital OaklandChildren's Hospital of Philadelphia; National Heart, Lung, and Blood Institute... et autres collaborateursComplétéThalassémieÉtats-Unis